Overview
Breaking the Cycle of Recurrent C. difficile: Update on Recent Data and Implications in Clinical Practice
Update on Recent C. difficile Data and Implications in Clinical Practice
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this video commentary, Dr. Paul Feuerstadt will discuss recent data on the treatment and prevention of recurrent C. difficile infection. He will also review emerging approaches and future directions in microbial restoration.
This educational activity is designed for physicians, pharmacists, nurse practitioners, physician assistants, nurses and other clinicians who care for patients at risk of serious gastrointestinal infection.
C. difficile and recurrent infections continue to exert significant burdens on patients, clinicians, and the healthcare system. This activity is the first in a series of educational activities that will address the latest data on treating and reducing the incidence of recurrence. Expert faculty will address identifying at-risk patients, selection of therapy to reduce the risk of recurrence, the role of the gut microbiome, and available and emerging approaches to reduce recurrent disease via restoration of the gut microbiome.
Upon completion of this activity, participants will be able to:
- Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
- Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
- Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
Sponsored by the Academy for Continued Healthcare Learning (ACHL)
Supported by an educational grant from Ferring Pharmaceuticals, Inc.
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Kelly Osborne, MSN, APRN, AGCNS-BC, CGRN, CFER (Nurse planner)
Clinical Nurse Specialist
Duke University Health System
Division of Gastroenterology
Durham, NC
Earl Campbell III, MD (Peer reviewer)
Yale University School of Medicine
New Haven, CT
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Kelly Osborne, MSN, APRN, AGCNS-BC, CGRN, CFER (Nurse planner)
Clinical Nurse Specialist
Duke University Health System
Division of Gastroenterology
Durham, NC
Earl Campbell III, MD (Peer reviewer)
Yale University School of Medicine
New Haven, CT
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
There is no conflict of interest for anyone with the ability to control the content of this activity except:
Paul Feuerstadt, MD, FACG, AGAF
Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Roche Diagnostics
Speakers' Bureau: Merck and Company
Kelly Osborne, MSN, APRN, AGCNS-BC, CGRN
Speakers' Bureau: Pentax Medical, Colowrap
Earl Campbell III, MD
Nothing to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes
There is no conflict of interest for anyone with the ability to control the content of this activity except:
Paul Feuerstadt, MD, FACG, AGAF
Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Roche Diagnostics
Speakers' Bureau: Merck and Company
Kelly Osborne, MSN, APRN, AGCNS-BC, CGRN
Speakers' Bureau: Pentax Medical, Colowrap
Earl Campbell III, MD
Nothing to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Melissa Stradal at 773-714-0705 x160
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education activity was approved by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)
Activity #22827
A maximum of 0.50 contact hours may be earned for successful completion of this activity.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education activity was approved by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)
Activity #22827
A maximum of 0.50 contact hours may be earned for successful completion of this activity.
